Prognostic relevance of epilepsy at presentation in glioblastoma patients

Sharon Berendsen; Meri Varkila; Jérôme Kroonen; Tatjana Seute; Tom J Snijders; Frans Kauw; Wim G M Spliet; Marie Willems; Christophe Poulet; Marike L Broekman; Vincent Bours; Pierre A Robe

doi:10.1093/neuonc/nov238

Prognostic relevance of epilepsy at presentation in glioblastoma patients

Sharon Berendsen, Meri Varkila, Jérôme Kroonen, Tatjana Seute, Tom J Snijders, Frans Kauw, Wim G M Spliet, Marie Willems, Christophe Poulet, Marike L Broekman, Vincent Bours, Pierre A Robe

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Epileptogenic glioblastomas are thought to convey a favorable prognosis, either due to early diagnosis or potential antitumor effects of antiepileptic drugs. We investigated the relationship between survival and epilepsy at presentation, early diagnosis, and antiepileptic drug therapy in glioblastoma patients.

METHODS: Multivariable Cox regression was applied to survival data of 647 consecutive patients diagnosed with de novo glioblastoma between 2005 and 2013 in order to investigate the association between epilepsy and survival in glioblastoma patients. In addition, we quantified the association between survival and valproic acid (VPA) treatment.

RESULTS: Epilepsy correlated positively with survival (HR: 0.75 (95% CI: 0.61-0.92), P < .01). This effect is independent of age, sex, performance status, type of surgery, adjuvant therapy, tumor location, and tumor volume, suggesting that this positive correlation cannot be attributed solely to early diagnosis. For patients who presented with epilepsy, the use of the antiepileptic drug VPA did not associate with survival when compared with patients who did not receive VPA treatment.

CONCLUSION: Epilepsy is an independent prognostic factor for longer survival in glioblastoma patients. This prognostic effect is not solely explained by early diagnosis, and survival is not associated with VPA treatment.

Original language	English
Pages (from-to)	700-706
Journal	Neuro-Oncology
Volume	18
Issue number	5
DOIs	https://doi.org/10.1093/neuonc/nov238
Publication status	Published - 2016

Keywords

epilepsy, glioblastoma, prognosis, survival, valproic acid

Access to Document

10.1093/neuonc/nov238

nov238Final published version, 168 KB

Cite this

@article{a95c9e21b7be4ad68df1dd46aa438b43,

title = "Prognostic relevance of epilepsy at presentation in glioblastoma patients",

abstract = "BACKGROUND: Epileptogenic glioblastomas are thought to convey a favorable prognosis, either due to early diagnosis or potential antitumor effects of antiepileptic drugs. We investigated the relationship between survival and epilepsy at presentation, early diagnosis, and antiepileptic drug therapy in glioblastoma patients.METHODS: Multivariable Cox regression was applied to survival data of 647 consecutive patients diagnosed with de novo glioblastoma between 2005 and 2013 in order to investigate the association between epilepsy and survival in glioblastoma patients. In addition, we quantified the association between survival and valproic acid (VPA) treatment.RESULTS: Epilepsy correlated positively with survival (HR: 0.75 (95% CI: 0.61-0.92), P < .01). This effect is independent of age, sex, performance status, type of surgery, adjuvant therapy, tumor location, and tumor volume, suggesting that this positive correlation cannot be attributed solely to early diagnosis. For patients who presented with epilepsy, the use of the antiepileptic drug VPA did not associate with survival when compared with patients who did not receive VPA treatment.CONCLUSION: Epilepsy is an independent prognostic factor for longer survival in glioblastoma patients. This prognostic effect is not solely explained by early diagnosis, and survival is not associated with VPA treatment.",

keywords = "epilepsy, glioblastoma, prognosis, survival, valproic acid",

author = "Sharon Berendsen and Meri Varkila and J{\'e}r{\^o}me Kroonen and Tatjana Seute and Snijders, {Tom J} and Frans Kauw and Spliet, {Wim G M} and Marie Willems and Christophe Poulet and Broekman, {Marike L} and Vincent Bours and Robe, {Pierre A}",

year = "2016",

doi = "10.1093/neuonc/nov238",

language = "English",

volume = "18",

pages = "700--706",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Prognostic relevance of epilepsy at presentation in glioblastoma patients

AU - Berendsen, Sharon

AU - Varkila, Meri

AU - Kroonen, Jérôme

AU - Seute, Tatjana

AU - Snijders, Tom J

AU - Kauw, Frans

AU - Spliet, Wim G M

AU - Willems, Marie

AU - Poulet, Christophe

AU - Broekman, Marike L

AU - Bours, Vincent

AU - Robe, Pierre A

PY - 2016

Y1 - 2016

N2 - BACKGROUND: Epileptogenic glioblastomas are thought to convey a favorable prognosis, either due to early diagnosis or potential antitumor effects of antiepileptic drugs. We investigated the relationship between survival and epilepsy at presentation, early diagnosis, and antiepileptic drug therapy in glioblastoma patients.METHODS: Multivariable Cox regression was applied to survival data of 647 consecutive patients diagnosed with de novo glioblastoma between 2005 and 2013 in order to investigate the association between epilepsy and survival in glioblastoma patients. In addition, we quantified the association between survival and valproic acid (VPA) treatment.RESULTS: Epilepsy correlated positively with survival (HR: 0.75 (95% CI: 0.61-0.92), P < .01). This effect is independent of age, sex, performance status, type of surgery, adjuvant therapy, tumor location, and tumor volume, suggesting that this positive correlation cannot be attributed solely to early diagnosis. For patients who presented with epilepsy, the use of the antiepileptic drug VPA did not associate with survival when compared with patients who did not receive VPA treatment.CONCLUSION: Epilepsy is an independent prognostic factor for longer survival in glioblastoma patients. This prognostic effect is not solely explained by early diagnosis, and survival is not associated with VPA treatment.

AB - BACKGROUND: Epileptogenic glioblastomas are thought to convey a favorable prognosis, either due to early diagnosis or potential antitumor effects of antiepileptic drugs. We investigated the relationship between survival and epilepsy at presentation, early diagnosis, and antiepileptic drug therapy in glioblastoma patients.METHODS: Multivariable Cox regression was applied to survival data of 647 consecutive patients diagnosed with de novo glioblastoma between 2005 and 2013 in order to investigate the association between epilepsy and survival in glioblastoma patients. In addition, we quantified the association between survival and valproic acid (VPA) treatment.RESULTS: Epilepsy correlated positively with survival (HR: 0.75 (95% CI: 0.61-0.92), P < .01). This effect is independent of age, sex, performance status, type of surgery, adjuvant therapy, tumor location, and tumor volume, suggesting that this positive correlation cannot be attributed solely to early diagnosis. For patients who presented with epilepsy, the use of the antiepileptic drug VPA did not associate with survival when compared with patients who did not receive VPA treatment.CONCLUSION: Epilepsy is an independent prognostic factor for longer survival in glioblastoma patients. This prognostic effect is not solely explained by early diagnosis, and survival is not associated with VPA treatment.

KW - epilepsy, glioblastoma, prognosis, survival, valproic acid

U2 - 10.1093/neuonc/nov238

DO - 10.1093/neuonc/nov238

M3 - Article

C2 - 26420896

SN - 1522-8517

VL - 18

SP - 700

EP - 706

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - 5

ER -

Prognostic relevance of epilepsy at presentation in glioblastoma patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this